All Stories

  1. World Pneumonia Day 2024: Fighting Pneumonia and Antimicrobial Resistance
  2. Impact of Empirical Treatment Recommendations From 2017 European Guidelines for Nosocomial Pneumonia
  3. A review of the value of point-of-care testing for community-acquired pneumonia
  4. Diabetes Mellitus and Pneumococcal Pneumonia
  5. Pneumococcal Serotypes Associated with Community-Acquired Pneumonia Hospitalizations in Adults in Spain, 2016–2020: The CAPA Study
  6. World Pneumonia Day 2023: the rising global threat of pneumonia and what we must do about it
  7. Ten Issues for Updating in Community-Acquired Pneumonia: An Expert Review
  8. Systematic review of ceftaroline fosamil in the management of patients with methicillin-resistantStaphylococcus aureuspneumonia
  9. Interventions to improve outcomes in community-acquired pneumonia
  10. The pharmacokinetic evaluation of omadacycline (Oral Only Dosing Regimen) for the treatment of Community-Acquired Bacterial Pneumonia (CABP)
  11. A Novel Approach to Temperature Profiling in Relation to Clinical Outcomes in Oncological Patients with Neutropenia
  12. Características clínicas y epidemiológicas de las muertes por dengue durante un brote en el norte del Perú
  13. Immunocompromised Host Pneumonia: Definitions and Diagnostic Criteria: An Official American Thoracic Society Workshop Report
  14. Remdesivir and survival outcomes in critically ill patients with COVID-19: A multicentre observational cohort study
  15. Risk factors associated with mortality among elderly patients with COVID-19: Data from 55 intensive care units in Spain
  16. Advances in molecular diagnostic tests for community-acquired pneumonia
  17. Machine-Learning Model for Mortality Prediction in Patients With Community-Acquired Pneumonia
  18. Estimating the risk of bacteraemia in hospitalised patients with pneumococcal pneumonia
  19. Host-targeted approaches to sepsis due to community-acquired pneumonia
  20. Respiratory viruses: their importance and lessons learned from COVID-19
  21. Early Recognition of Low-Risk SARS-CoV-2 Pneumonia
  22. Aspiration pneumonia
  23. Ceftaroline in severe community-acquired pneumonia
  24. Steroid therapy and antiviral treatment in SARSCoV-2 pneumonia: clinical contexts and indications
  25. Biomarcadores biológicos en las enfermedades respiratorias
  26. [Translated article] Biological Biomarkers in Respiratory Diseases
  27. What's Next in Pneumonia?
  28. Severe Infections Due to Respiratory Viruses
  29. Invasive pulmonary aspergillosis among intubated patients with SARS-CoV-2 or influenza pneumonia: a European multicenter comparative cohort study
  30. Management of pneumonia in critically ill patients
  31. COVID-19 in patients aged 80 years and over during the peaks of the first three pandemic waves at a Spanish tertiary hospital
  32. Impact on in-hospital mortality of ceftaroline versus standard of care in community-acquired pneumonia: a propensity-matched analysis
  33. Outcomes of Critically ill Very old patients with Acute Respiratory Distress Syndrome and Community-Acquired Pneumonia
  34. Impact on in-hospital mortality of Ceftaroline versus standard of care in Community-Acquired Pneumonia: A Propensity Matched Analysis
  35. The Value of C-Reactive Protein-to-Lymphocyte Ratio in Predicting the Severity of SARS-CoV-2 Pneumonia
  36. Prediction of ventilator-associated pneumonia outcomes according to the early microbiological response: a retrospective observational study
  37. Pulse oximetry is an essential tool that saves lives: a call for standardisation
  38. Predictive Performance of Risk Factors for Multidrug-Resistant Pathogens in Nosocomial Pneumonia
  39. Pneumonia
  40. Lymphopenia Is Associated With Poor Outcomes of Patients With Community-Acquired Pneumonia and Sepsis
  41. Validation of a Prediction Score for Drug-Resistant Microorganisms in Community-acquired Pneumonia
  42. PES Pathogens in Elderly Patients with Acquired Pneumonia in the Community
  43. Awareness and Pneumonia knowledge: where to start educating?
  44. Methicillin-susceptible Staphylococcus aureus in Community-Acquired Pneumonia: Risk Factors and Outcomes
  45. Systemic Inflammatory Response and Outcomes in Community-Acquired Pneumonia Patients Categorized According to the Smoking Habit or Presence of Chronic Obstructive Pulmonary Disease
  46. SARS-CoV-2–induced Acute Respiratory Distress Syndrome: Pulmonary Mechanics and Gas-Exchange Abnormalities
  47. Promoting the use of social networks in pneumonia
  48. Difficult to treat microorganisms in patients aged over 80 years with community-acquired pneumonia: the prevalence of PES pathogens
  49. Advances in molecular diagnostic tests for pneumonia
  50. Community-acquired pneumonia in critically ill very old patients: a growing problem
  51. Defining Community-Acquired Pneumonia as a Public Health Threat: Arguments in Favor from Spanish Investigators
  52. Can Artificial Intelligence Improve the Management of Pneumonia
  53. Reply to Musher
  54. Macrolide combination therapy for hospitalised CAP patients? An individualised approach supported by machine learning
  55. Pneumocystis pneumonia in the twenty-first century: HIV-infected versus HIV-uninfected patients
  56. Prevalence and risk factors of sepsis in very old patients with CAP
  57. Ventilator-Associated Pneumonia and PaO2/FIO2 Diagnostic Accuracy: Changing the Paradigm?
  58. Risk and Prognostic Factors in Very Old Patients with Sepsis Secondary to Community-Acquired Pneumonia
  59. non invasive diagnosis of nosocomial pneumonia
  60. Impact of Cefotaxime Non-susceptibility on the Clinical Outcomes of Bacteremic Pneumococcal Pneumonia
  61. Risk and Prognostic Factors in Very Old Patients with Sepsis Secondary to Community-Acquired pneumonia
  62. lymphopenia predicts mortality in patients with ICU pneumonia
  63. Addendum: Cillóniz, C.; Dominedò, C.; Nicolini, A.; Torres, A. PES Pathogens in Severe Community-Acquired Pneumonia. Microorganisms 2019, 7, 49
  64. Evaluation of the Magicplex™ Sepsis Real-Time Test for the Rapid Diagnosis of Bloodstream Infections in Adults
  65. Multidrug Resistant Gram-Negative Bacteria in Community-Acquired Pneumonia
  66. PES Pathogens in Severe Community-Acquired Pneumonia
  67. An international perspective on hospitalized patients with viral community-acquired pneumonia
  68. Early noninvasive ventilation treatment for respiratory failure due to severe community-acquired pneumonia
  69. Community-acquired pneumonia as an emergency condition
  70. Effect of Combined β-Lactam/Macrolide Therapy on Mortality According to the Microbial Etiology and Inflammatory Status of Patients with Community-Acquired Pneumonia
  71. Reply to Head and Keynan
  72. Drugs that increase the risk of community-acquired pneumonia: a narrative review
  73. Treating HIV-Positive/Non-AIDS Patients for Community-Acquired Pneumonia with ART
  74. Clinical Approach to Community-acquired Pneumonia
  75. Corticosteroid treatment in critically ill patients with severe influenza pneumonia: a propensity score matching study
  76. Inflammatory response depends on time since onset of symptoms in pneumonia
  77. MagicplexTM Sepsis real-time test for the rapid diagnosis of bloodstream infections in adults
  78. Twenty-year trend in mortality among hospitalized patients with pneumococcal community-acquired pneumonia
  79. Burden and risk factors forPseudomonas aeruginosacommunity-acquired pneumonia: a multinational point prevalence study of hospitalised patients
  80. Community-acquired bacterial pneumonia in adult HIV-infected patients
  81. Microorganisms resistant to conventional antimicrobials in acute exacerbations of chronic obstructive pulmonary disease
  82. Community-acquired Pneumonia and Acute Respiratory Distress Syndrome
  83. Characteristics and Management of Community-Acquired Pneumonia in the Era of Global Aging
  84. Community-Acquired Legionella Pneumonia in Human Immunodeficiency Virus–Infected Adult Patients: A Matched Case-Control Study
  85. Burden of pneumococcal community-acquired pneumonia in adults across Europe: A literature review
  86. Effectiveness of combination therapy versus monotherapy with a third-generation cephalosporin in bacteraemic pneumococcal pneumonia: A propensity score analysis
  87. Acute respiratory distress syndrome in mechanically ventilated patients with community-acquired pneumonia
  88. Detection of human cytomegalovirus in bronchoalveolar lavage of intensive care unit patients
  89. Severe community-acquired pneumonia: Characteristics and prognostic factors in ventilated and non-ventilated patients
  90. New Sepsis Definition (Sepsis-3) and Community-acquired Pneumonia Mortality. A Validation and Clinical Decision-Making Study
  91. Respiratory infection: insights from Assembly 10 of the European Respiratory Society 2017 Annual Congress
  92. Has Mortality of Community-Acquired Pneumonia Really Reduced?
  93. Predictors of treatment failure and clinical stability in patients with community acquired pneumonia
  94. Adjuvant therapies in critical care: steroids in community-acquired pneumonia
  95. Investigational drugs in phase I and phase II clinical trials for the treatment of community-acquired pneumonia
  96. Lymphopenic Community Acquired Pneumonia (L-CAP), an Immunological Phenotype Associated with Higher Risk of Mortality
  97. Evaluation of severity score-guided approaches to macrolide use in community-acquired pneumonia
  98. The burden of PCV13 serotypes in hospitalized pneumococcal pneumonia in Spain using a novel urinary antigen detection test. CAPA study
  99. Time to blood culture positivity as a predictor of clinical outcomes and severity in adults with bacteremic pneumococcal pneumonia
  100. Community-Acquired Pneumococcal Pneumonia in Virologically Suppressed HIV-Infected Adult Patients
  101. Treatment with macrolides and glucocorticosteroids in severe community-acquired pneumonia: A post-hoc exploratory analysis of a randomized controlled trial
  102. Invasive Disease vs Urinary Antigen-Confirmed Pneumococcal Community-Acquired Pneumonia
  103. Risk factors for community-acquired pneumonia in adults
  104. Antibiotic therapy prior to hospital admission is associated with reduced septic shock and need for mechanical ventilation in patients with community-acquired pneumonia
  105. Typical Presentation of Legionella pneumophila Community-Acquired Pneumonia
  106. Research in community-acquired pneumonia: the next steps
  107. Seasonality of pathogens causing community-acquired pneumonia
  108. Microbial Etiology of Pneumonia: Epidemiology, Diagnosis and Resistance Patterns
  109. Laboratory diagnosis of pneumonia in the molecular age
  110. Delay in diagnosis of influenza A (H1N1)pdm09 virus infection in critically ill patients and impact on clinical outcome
  111. Clinical management of community acquired pneumonia in the elderly patient
  112. Community-Acquired Pneumonia 2000-2015: What is New?
  113. Response
  114. Community-Acquired Pneumonia Due to Multidrug- and Non–Multidrug-Resistant Pseudomonas aeruginosa
  115. Community-acquired pneumonia related to intracellular pathogens
  116. Predictive and prognostic factors in patients with blood-culture-positive community-acquired pneumococcal pneumonia
  117. What is the clinical relevance of drug-resistant pneumococcus?
  118. Multilobar bilateral and unilateral chest radiograph involvement: implications for prognosis in hospitalised community-acquired pneumonia
  119. Pneumococcal vaccination
  120. Impact of neuraminidase inhibitors on influenza A(H1N1)pdm09-related pneumonia: an individual participant data meta-analysis
  121. Procalcitonin (PCT) levels for ruling-out bacterial coinfection in ICU patients with influenza: A CHAID decision-tree analysis
  122. Severe community-acquired pneumonia: Corticosteroids as adjunctive treatment to antibiotics
  123. Bronchiectasis in rare pulmonary diseases: A case series
  124. Bacteraemia in outpatients with community-acquired pneumonia
  125. Polymicrobial community-acquired pneumonia: An emerging entity
  126. Sensitivity, Specificity, and Positivity Predictors of the Pneumococcal Urinary Antigen Test in Community-Acquired Pneumonia
  127. Bacteraemia in outpatient with community-acquired pneumonia
  128. Ceftobiprole for the treatment of pneumonia: a European perspective
  129. Streptococcus pneumoniae-associated pneumonia complicated by purulent pericarditis: case series
  130. Microbiology and outcomes of community acquired pneumonia in non cystic-fibrosis bronchiectasis patients
  131. New antimicrobial approaches to gram positive respiratory infections
  132. Macrolide resistance and outcomes of patients with Streptococcus pneumoniae pneumonia.
  133. Risk Factors Associated with Potentially Antibiotic-Resistant Pathogens in Community-Acquired Pneumonia
  134. Bacteraemia and antibiotic-resistant pathogens in community acquired pneumonia: risk and prognosis
  135. Severe community-acquired pneumonia: Severity and management
  136. Noninvasive ventilation for acute respiratory failure due to community-acquired pneumonia: A concise review and update
  137. Clinical Management of Bacterial Pneumonia
  138. Viral infections
  139. Detection of Pneumonia Associated Pathogens Using a Prototype Multiplexed Pneumonia Test in Hospitalized Patients with Severe Pneumonia
  140. Severity and outcomes of community acquired pneumonia in asthmatic patients
  141. Predicting treatment failure in patients with community acquired pneumonia: a case-control study
  142. Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data
  143. Lung abscess due to Streptococcus pneumoniae: a case series and brief review of the literature
  144. Epidemiology, antibiotic therapy and clinical outcomes of healthcare-associated pneumonia in critically ill patients: a Spanish cohort study
  145. Community-acquired lung respiratory infections in HIV-infected patients: microbial aetiology and outcome
  146. IgA level in plasma as a differential factor for influenza infection in severe viral pneumonia
  147. Pneumococcal disease: Epidemiology and new vaccines
  148. Community-acquired viral pneumonia in human immunodeficiency virus infected patients
  149. Phenotyping community-acquired pneumonia according to the presence of acute respiratory failure and severe sepsis
  150. Predicting Community-Acquired Pneumonia Etiology: Response
  151. A Worldwide Perspective of Nursing Home-Acquired Pneumonia Compared With Community-Acquired Pneumonia
  152. IgM levels in plasma predict outcome in severe pandemic influenza
  153. Microbial aetiology of healthcare associated pneumonia in Spain: a prospective, multicentre, case–control study
  154. Impact of Age and Comorbidity on Cause and Outcome in Community-Acquired Pneumonia
  155. Multidrug-resistant pathogens in hospitalised patients coming from the community with pneumonia: a European perspective: Table 1
  156. Influence of Previous Use of Inhaled Corticoids on the Development of Pleural Effusion in Community-acquired Pneumonia
  157. Thrombocytosis Is a Marker of Poor Outcome in Community-Acquired Pneumonia
  158. Epidemiology, Clinical Features, and Prognosis of Elderly Adults with Severe Forms of Influenza A (H1N1)
  159. Systemic corticosteroids for community-acquired pneumonia: Reasons for use and lack of benefit on outcome
  160. Macrolide-based regimens in absence of bacterial co-infection in critically ill H1N1 patients with primary viral pneumonia
  161. Influenza A (H1N1) Pneumonia
  162. Pulmonary complications of pneumococcal community-acquired pneumonia: incidence, predictors, and outcomes
  163. Invasive Pneumococcal Disease Today
  164. Bacterial co-infection with H1N1 infection in patients admitted with community acquired pneumonia
  165. Entendimento da mortalidade em pneumonia pneumocócica bacterêmica
  166. Cytokine Activation Patterns and Biomarkers Are Influenced by Microorganisms in Community-Acquired Pneumonia
  167. Pulmonary Complications Of Pneumococcal CAP: Incidence, Predictors, And Outcomes
  168. Corticosteroids In Community-Acquired Pneumonia: Therapeutic Reasons And Outcomes
  169. Influence Of Long-Term Use Of Inhaled Corticoids On The Development Of Pleural Effusion In Community Acquired Pneumonia
  170. Thrombocytosis Is A Diagnostic And Prognostic Marker In Community-Acquired Pneumonia
  171. Corticosteroid therapy in patients with primary viral pneumonia due to pandemic (H1N1) 2009 influenza
  172. Community-acquired pneumonia in outpatients: aetiology and outcomes
  173. CD4+ cell counts and HIV-RNA levels do not predict outcomes of community-acquired pneumonia in hospitalized HIV-infected patients
  174. CAP IN COPD PATIENTS
  175. Clinical relevance of mixed respiratory viral infections in adults with influenza A H1N1
  176. First influenza season after the 2009 pandemic influenza: report of the first 300 ICU admissions in Spain
  177. Microbial aetiology of community-acquired pneumonia and its relation to severity
  178. Community-acquired polymicrobial pneumonia in the intensive care unit: aetiology and prognosis
  179. Pandemic and post-pandemic Influenza A (H1N1) infection in critically ill patients
  180. Influenza pneumonia: a comparison between seasonal influenza virus and the H1N1 pandemic
  181. Correction
  182. Factors associated with inflammatory cytokine patterns in community-acquired pneumonia
  183. Severe Mixed Community Acquired Pneumoniae
  184. Community-acquired Pneumonia In Outpatients: Microbial Etiology
  185. INDICATION OF PLEURAL DRAINAGE IN PARAPNEUMONIC EFFUSION: ADHERENCE TO THE AMERICAN COLLEGE OF CHEST PHYSICIANS’ GUIDELINES
  186. PARAPNEUMONIC EFFUSIONS ACCORDING TO THE CLASSIFICATION OF THE AMERICAN COLLEGE OF CHEST PHYSICIANS: CLINICAL CHARACTERISTICS
  187. Healthcare-associated Pneumonia (HCAP): Clinical Features And Biomarkers
  188. Nursing home-acquired pneumonia: a 10 year single-centre experience
  189. Impact of Smoking Habit on the Etiology of Community-Acquired Pneumonia (CAP).
  190. Community-Acquired Pneumonia: Etiology and Severity Scores.
  191. Complicated Pneumococcal Pneumonia in Adults.
  192. Severe community-acquired pneumonia